The pathogenesis of Alzheimer's disease (AD), the most prevalent form of dementia,
remains unclear. Over the past few years, evidence has accumulated indicating that …

Increasing evidence links metabolic disorders with neurodegenerative processes including
Alzheimer's disease (AD). Late AD is associated with amyloid (Aβ) plaque accumulation …

Amyloid-β (Aβ) deposition and tau-dependent pathology are key features of Alzheimer's
disease (AD). However, to date, approaches aimed at counteracting these two pathogenic …

Oxidative stress, bioenergetic failure and mitochondrial dysfunction are all implicated in the
etiology of neurodegenerative diseases such as Alzheimer's disease (AD). The …

Decreases of the sex steroids, testosterone and estrogen, are associated with increased risk
of Alzheimer's disease. Testosterone and estrogen supplementation improves cognitive …

Neuronal cell impairment, such as that induced by amyloid-beta (Aβ) protein, is a process
with limited therapeutic interventions and often leads to long-term neurodegeneration …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting more than
47.5 million people worldwide. Metabolic impairments are common hallmarks of AD, and …

Accumulating evidence suggests that mitochondria are important targets for the actions of
estrogens and studies indicated that localization of estrogen receptor ß (ERß) in neuronal …

Neuroprotection by estrogen in the CNS is well‐documented and comprises the intricate
regulation of cell–cell communication between neurons and supportive non‐neuronal glial …

Mitochondrial aberrations are observed in human Alzheimer's disease (AD) and in medical
conditions that increase the risk of this disorder, suggesting that mitochondrial dysfunction …